Wound-Healing Combo Product Jurisdiction Should Be Clarified – Ex-FDAer
This article was originally published in The Gray Sheet
Executive Summary
The regulatory pathway for wound-healing combination products should be elucidated because they increasingly are assigned to CBER and not the device center, according to The Biologics Consulting Group Senior Consultant Darin Weber, PhD
You may also be interested in...
Device Review Templates Are Milestones On Road To “Critical Path” – CBER
The Center for Biologics Evaluation & Research is flagging areas of the device review process that can be clarified through "templates" to guide staff and sponsors
Potential Jurisdictional Change Draws Protest From Wound Product Firms
Wound healing products for which a primary mode of action cannot be elucidated should remain under the jurisdiction of FDA's device center, according to Apligraf manufacturer Organogenesis
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.